Three blood biomarker categories were evaluated in the study: phosphorylated tau 181, glial acidic proteins, and neurofilament light chain proteins.
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the first Phase 3 study to show a notable increase in event-free survival in the early stages of head and neck squamous cell carcinoma when using […]
Many Americans suffer from long-term inflammatory skin disorders that have no known etiology and frequently no effective treatments other than symptom control. A recent study may open the door to personalized treatment and diagnostic tests based on precision medicine. Their findings were published in the journal Scientific Reports. We isolated […]
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.
Researchers at St. Jude Children’s Research Hospital report findings from a novel and promising treatment for the uncommon neurological disease.
Utilizing reduced Takumi-shaped DNA nanostructures, researchers create optimal DNA hydrogels with possible biological uses.
According to the researchers, these recurring patterns suggest potential therapeutic targets meant to prevent or slow the progression of cancer.
Rare yet debilitating disorders, Dravet syndrome, and other developing epileptic encephalopathies induce a variety of symptoms in children, such as seizures, intellectual incapacity, and even unexpected death. The majority of cases are brought on by a genetic mutation; variations in the sodium channel gene SCN1A are most frequently the cause […]
